2-Chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia

被引:36
作者
Robak, T
BlasinskaMorawiec, M
Krykowski, E
Hansz, J
Komarnicki, M
Kazimierczak, M
Konopka, L
Maj, S
Hellmann, A
Zaucha, JM
Urasinski, L
Zdziarska, B
KotlarekHaus, S
UsnarskaZubkiewicz, L
Kuratowska, Z
DwilewiczTrojaczek, J
Holowiecki, J
KrawczykKulis, M
Grieb, P
机构
[1] 2nd Department of Internal Medicine, Med. Univ. of Lódź, Poznañ
[2] Department of Hematology, Academy of Medicine, Poznañ
[3] Inst. of Hematol. and Transfusiology, Warsaw
[4] Department of Hematology, Univ. Med. School of Gdańsk, Szczecin
[5] Department of Hematology, Institute of Internal Medicine, Pomorian Academy of Medicine, Szczecin
[6] Department of Hematology, Academy of Medicine, Wroclaw
[7] Department of Hematology, Academy of Medicine, Warsaw
[8] Department of Hematology, Silesian Academy of Medicine, Katowice
[9] Medical Research Center, Polish Academy of Sciences, Warsaw
[10] Department of Internal Medicine, Med. Univ. of Lódź, 93-513 Lódz
关键词
2-chlorodeoxyadenosine; hairy cell leukemia; efficiency; side effects;
D O I
10.3109/10428199609051736
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Forty one patients with hairy cell leukemia (HCL) were treated with 2-chloro-deoxyadenosine (2-CdA) administered in various schedules. Complete remission (CR) was achieved in 31 (76%) patients and partial remission (PR) in 9 (22%). The mean duration of remission (CR + PR) was 25.2 months (range 9-45 months). One patient did not respond to therapy. Twelve out of 16 patients (75%) achieved CR after 5-day intravenous infusions of 2-CdA and 19 out of 25 patients (76%) after 7-day courses. In 19 out of 23 patients (82.6%) CR was achieved after intermittent 2-hour infusions and in 12 out of 18 (66.7%) after continuous 24-hour infusion. The differences were not statistically significant. Side effects of 2-CdA were similar in both groups except for infections, which were less frequently observed in the group treated for 5 days. The results of our study suggest that 2-CdA can be effectively administered to patients with HCL using 5-day courses and a 2-hour daily infusion.
引用
收藏
页码:107 / 111
页数:5
相关论文
共 23 条
[1]   LEUKEMIC RETICULOENDOTHELIOSIS [J].
BOURONCLE, BA ;
WISEMAN, BK ;
DOAN, CA .
BLOOD, 1958, 13 (07) :609-630
[2]   PENTOSTATIN INDUCES DURABLE REMISSIONS IN HAIRY-CELL LEUKEMIA [J].
CASSILETH, PA ;
CHEUVART, B ;
SPIERS, ASD ;
HARRINGTON, DP ;
CUMMINGS, FJ ;
NEIMAN, RS ;
BENNETT, JM ;
OCONNELL, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (02) :243-246
[3]  
CATOVSKY D, 1990, LYMPHOID LEUKAEMIAS, P156
[4]   HAIRY-CELL LEUKEMIA - CURRENT STATUS [J].
CHANG, KL ;
STROUP, R ;
WEISS, LM .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1992, 97 (05) :719-738
[5]   IMMUNOENZYMATIC LABELING OF MONOCLONAL-ANTIBODIES USING IMMUNE-COMPLEXES OF ALKALINE-PHOSPHATASE AND MONOCLONAL ANTI-ALKALINE PHOSPHATASE (APAAP COMPLEXES) [J].
CORDELL, JL ;
FALINI, B ;
ERBER, WN ;
GHOSH, AK ;
ABDULAZIZ, Z ;
MACDONALD, S ;
PULFORD, KAF ;
STEIN, H ;
MASON, DY .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1984, 32 (02) :219-229
[6]  
ESTEY EH, 1992, BLOOD, V79, P882
[7]  
FILLEUL B, 1994, LEUKEMIA, V8, P1153
[8]  
GOLOMB HM, 1987, BLOOD, V69, P979
[9]  
HAKIMIAN D, 1993, BLOOD, V82, P1798
[10]  
JULIUSSON G, 1992, BLOOD, V79, P888